mRNA vaccine testing for Omicron subject to regulatory approvals: Gennova Biopharmaceutical

[email protected]21 Feb, 2022News

The testing of Gennova Biopharmaceutical's mRNA vaccine for the Omicron variant of COVID-19 is subject to regulatory approvals, the company's official spokesperson informed on Monday. The company spokesperson said, "Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals."Meanwhile, the Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also completed the recruitment of phase 3 data.